Andere talen Erasca, Inc.

Aandelen

ERAS

US29479A1088

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,79 ^USD	-2,72%		-21,83%	-15,96%

02/04	ERASCA, INC. : Een koopadvies van Goldman Sachs	ZM
27/03	Erasca, Inc. Rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

North American Morning Briefing : Powell Awaited -2-	03/04
Erasca Announces $45 Million Oversubscribed Private Placement Financing	28/03
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results	27/03
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
Erasca, Inc. announced that it expects to receive $45 million in funding	27/03
Erasca Enters Two Supply Deals With Novartis for Trametinib	14/02
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	14/02
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	14/02
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01/02
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01/02
North American Morning Briefing : Boeing Drags -2-	08/01
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	11/12
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	11/12
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	11/12
ErascaCEO Bought Shares Worth $1,696,179, According to a Recent SEC Filing	07/12
Erasca Completes Dose Escalation in Phase 1 Thunderbbolt-1 Trial; Extends Cash Runway to 2026	28/11
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway	28/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Erasca, Inc.

Aandelen

ERAS

US29479A1088

Andere talen

Filters